Heramed Ltd · ASX:HMD
Heramed — Investor Presentation (June 2020)
20 slides from Heramed's investor presentation, Jun 5, 2020
Slide 1: A leading telehealth technology provider for maternity care
1 A leading telehealth technology provider for maternity care Company Presentation June 2020 This announcement has been approved by the Board of Directors
Slide 2: Transformed Global Outlook for Telehealth
2 Transformed Global Outlook for Telehealth COVID-19 presents an opportunity to fast-track adoption of digital health • Healthcare globally is experiencing a rapid Global Telemedicine Market (USD$bn)1 paradigm shift $175.5bn • Governments, Insurers and providers are increasingly adopting and reimbur
Slide 3: Cost of maternity complications are significant
3 Cost of maternity complications are significant Considerable opportunity exists to reduce costs and improve maternity care US$111bn US Maternal Healthcare Market Postpartum Depression Preeclampsia C-section Preterm Birth US$14bn US$2.2bn US$9bn US$26bn
Slide 4: The HeraMED Opportunity
4 The HeraMED Opportunity Well placed to capitalise on significant opportunity in maternal telehealth globally Proprietary platform using Developed by medical The only medical grade, Patent pending protected hardware and software engineers and clinical clinically validated, digital hardware, softwar
Slide 5: HeraCARE: Digital Pregnancy Monitoring Platform
5 HeraCARE: Digital Pregnancy Monitoring Platform Delivering medical grade technology supported by qualified healthcare professionals Secure Care Manager Dashboard Comms Channels Maternity Companion App HeraBEAT foetal heart rate monitor Activity Tracker Urine testing Weight Measurement Blood Pressu
Slide 6: HeraBEAT Device
6 HeraBEAT Device Medical grade foetal & maternal heart rate monitor for home use • Foetal & maternal heart rate An innovative connected device that is accurate, monitoring to same standard and affordable and scientifically optimised accuracy as hospitals • FDA cleared connected device, approved for
Slide 7: HeraMED Value Proposition
7 HeraMED Value Proposition End-to-end solution drives value for multiple stakeholders Expectant Mothers Clinical Staff Hospitals Empowerment Improved outcomes Operational Efficiencies Convenience Patient satisfaction Customer Loyalty Peace of Mind Reduced burden Innovation Identity Employers Insura
Slide 8: HeraCARE Business Model
8 HeraCARE Business Model HeraCARE will be sold through a strategic range of channel partners Enterprise Agreement: Healthcare Healthcare providers a) One-off establishment fee Providers Integrate platform into b) Per User/Per Month HeraCARE SaaS fee operations c) One-off hardware HeraBEAT purchase
Slide 9: Commercialisation Strategy – B2B2C
9 Commercialisation Strategy – B2B2C Partnership model to fast-track adoption of HeraCARE Strategic pathway Progress 1 Build best in class proprietary solution with leading healthcare providers Complete 2 Pilots and clinical validation trials Well Progressed 3 Align with key opinion leaders in the i
Slide 10: Route to Success
10 Route to Success Align with global leading healthcare providers & key opinion leaders in maternity care Mayo Clinic MedTech Edge Hapvida One of the largest not‐for‐profit, academic health systems in the U.S., One of Brazil’s largest healthcare Privately owned global trading with $14 billion in an
Slide 11: Strategy & Milestones
11 Strategy & Milestones HeraMED has a clear execution strategy, with multiple short & medium-term milestones Q4 2018 Q1 2019 Q3 2019 Q4 2019 Q4 2019 Q1 2020 Collaboration Market Germany HeraBEAT FDA US Market strategy US Collaborators with Key Validation, Distribution 510k clearance & Key hires kic
Slide 12: Investment Highlights
12 Investment Highlights HeraMED is well placed to capitalise on strong growth in maternity care telehealth COVID-19 presents Value created for all Only medical grade, Clear competitive opportunity to fast-track stakeholders underpins clinically validated, advantage with significant adoption of tele
Slide 13: Appendix
13 Appendix
Slide 14: Capital Raising Details
14 Capital Raising Details Intention to raise $2.32m, with an additional $1.5m Share Purchase Plan offered to existing shareholders TRANSACTION OVERVIEW Offer Price A$0.090 per share (21.7% discount to last close price of $0.115) Use of Funds Placement Shares 25,804,659 Offer Size $2.32m • Funds wil
Slide 15: Capital Structure
15 Capital Structure Volume (m) Capital Structure $0.30 20 Shares on Issue 103.9m 18 Share Price (29 May 2020) $0.115 16 12-month Range 0.33 / 0.06 14 $0.20 Market Cap A$11.94m 12 Cash Balance (31 March 2020) USD $1.2m 10 Top 5 Shareholders Holding (%) 8 Altshuler Shaham Trusts Ltd <Holley Pharma Co
Slide 16: Board of Directors
16 Board of Directors Dr. Ron Weinberger – Non-Executive Chairman • Highly experienced business executive, with strong scientific background and international span| Former Board Director, President and CEO of Nanosonics Ltd. ASX: NAN, Mkt cap ~$2 Billion | CEO and Managing Director of EMVision Ltd.
Slide 17: Route to Market
17 Route to Market Align with global leading healthcare providers & key opinion leaders in maternity care OB NEST CLINICALLY VALIDATED 5 YEARS OF RESEARCH 2011-2016 14 REDUCED 8 Visits From 14 to 8 1.41 LOWERED OB Nest aimed to de-medicalize the experience of 1.34 Pregnancy Stress pregnancy by provi
Slide 18: Providing a hospital grade standard for home
18 Providing a hospital grade standard for home HeraMED technology mirrors the gold standard, hospital grade monitoring machine 210 190 170 Fetal Heart rate [BPM] 150 130 Philips HeraBEAT 110 90 Hundreds of internal, external, bench and clinical tests prove HeraBEAT’s results are as accurate as the
Slide 19: Disclaimer
19 Disclaimer Important notice regarding forward looking statements This document contains a general summary of the company and is provided for information purposes only. For full details please review HeraMED Limited ACN 626 295 314 (HeraMED) ASX page - https://www.asx.com.au/asx/share-price-resear
Slide 20: HeraMED
20 HeraMED David Groberman, CEO and Co-Founder M: +972 52 699 1188 E: David@hera-med.com Jonathan Hart, Company Secretary M: +61 2 8379 2961 E: Jonathan@hera-med.com Henslow Tim Chapman, Director M: +61 419 897 062 E: tchapman@henslow.com